CompletedNot Applicable

HILT for Meralgia Paresthetica

Egypt62 participantsStarted 2023-06-01

Plain-language summary

This randomized controlled trial aims to investigate the efficacy of High-Intensity Laser Therapy (HILT) in the management of Meralgia Paresthetica (MP), a peripheral neuropathy causing pain, numbness, and tingling in the thigh region. Participants with MP will be randomly allocated to either the HILT or sham HILT (control) group. The study will evaluate the effects of HILT on pain intensity, functional outcomes, and quality of life. Findings from this trial will provide insights into the potential benefits of HILT as a non-invasive and safe treatment option for patients with MP.

Who can participate

Age range

35 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Meralgia Paresthetica, confirmed by a neurologist or a specialist in neuromuscular disorders, based on clinical signs and symptoms, and supported by nerve conduction studies. * Presence of pain, numbness, or tingling in the anterolateral thigh for at least three months. * Aged between 35 and 55 years. * Willing and able to provide informed consent. * Able to comply with the study protocol and attend all treatment sessions and follow-up assessments. Exclusion Criteria: * Previous surgical treatment for Meralgia Paresthetica. * Concomitant lower back or hip pain due to other causes, such as lumbar radiculopathy, hip joint pathology, or trochanteric bursitis. * Presence of other neuromuscular or nerve compression disorders such as diabetic neuropathy * Significant trauma or surgery to the affected thigh or lumbar spine within the past six months. * Pregnancy or planning to become pregnant during the study period. * Known contraindications to High-Intensity Laser Therapy, such as active skin infection, malignancy, or photosensitivity disorders. * Current use of anticoagulant medications or immunosuppressive therapy.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Changes in Pain Intensity

Timeframe: Changes measured at Baseline, immediately post-treatment (4 weeks), and at 1- and 3-month follow-ups

Trial details

NCT IDNCT05893732

SponsorAhram Canadian University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-08

View on ClinicalTrials.gov More Meralgia Paresthetica trials